THU0369 Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis With High Retention Rate: 3-Year Results From Phase Iii Trial, Measure 2

doi 10.1136/annrheumdis-2017-eular.1295

Full Text

Abstract

Available in

Date

Authors

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study

ACR Open Rheumatology
2019English

Efficacy, Safety, and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: A Randomized, Double-Blind Phase 3 Study, MEASURE 3

Arthritis Research & Therapy
2017English

FRI0494 Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis: 2-Year Results From the Future 2 Study

2017English

Correction To: Secukinumab: A Review in Ankylosing Spondylitis

Drugs
Pharmacology
2019English

The High Prevalence of Infections and Allergic Symptoms in Patients With Ankylosing Spondylitis Is Associated With Clinical Symptoms

Clinical Rheumatology
MedicineRheumatology
2006English

Sustained Response to Anakinra in Ankylosing Spondylitis

Rheumatology
RheumatologyPharmacology
2007English

The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology
AllergyImmunology
2019English

Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Relapsing Polychondritis Following Treatment With Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature

Case Reports in Rheumatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy